The quarter’s EPS was worse than expected. CG Oncology reported a net loss of $0.90 per share versus published pre-release estimates of roughly $0.66–$0.68 per share loss, a clear miss; revenue comparisons are less reliable because available estimates were inconsistent. (Income Statement)
| $ millions, except per-share data | Q2 2026 | Q2 2025 | Change / comparison |
|---|---|---|---|
| Total revenue | $1.157 | $0.000 | New commercial and development revenue (Income Statement) |
| R&D expense | $54.657 | $31.331 | Higher (Income Statement) |
| G&A expense | $28.976 | $17.410 | Higher (Income Statement) |
| Net loss | $(79.056) | $(41.426) | Larger loss (Income Statement) |
| Net loss per share | $(0.90) | $(0.54) | Worse by $0.36 (Income Statement) |
| Cash, cash equivalents and marketable securities | $1,028.278 | $742.155 at Dec. 31, 2025 | Company says runway through 2029 (Balance Sheet Data; Financial Highlights) |
The more consequential update is the financing capacity. The company registered an additional $500.0 million of common-stock sales under its ATM facility after previously selling approximately $550.0 million through the same agreement (Item 8.01). This does not mean all $500 million will be issued immediately, but it materially expands potential dilution and signals that management wants financing flexibility ahead of pivotal clinical and regulatory milestones.
The pipeline timetable was maintained, not accelerated. PIVOT-006 topline data remain anticipated in the near term, and BLA completion for the high-risk BCG-unresponsive indication remains targeted for the fourth quarter of 2026 (Anticipated 2026 Milestones). The filing provides no new efficacy data, so the central investment question remains unresolved until the Phase 3 readout.
Cash strength offsets some financing concern but does not erase the miss. Cash fell from approximately $1.1 billion at March 31, 2026 to approximately $1.0 billion at June 30, 2026, while R&D increased to $54.7 million from $31.3 million year over year and G&A rose to $29.0 million from $17.4 million (Financial Highlights). The company still claims funding through 2029, but the weaker-than-expected quarterly loss plus expanded ATM creates a mildly negative read ahead of the more important clinical catalysts.
Read the original 8-K on SEC EDGAR ↗